Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You're sharp today Axe. Cheered me up too.
Thanks
Axe C, thanks for clarifying and good to hear!
RM is absolutely referring to the New funded trials via NiH. If you read the script the new funding is for trials that included other Viruses.
Then listen to RM and a coded message is given that very interested parties/trials that are in process of setting up multi virus trials to test effectiveness of anti-virals across a range of infections is good news for SNG. RM states this.
This is a direct reference to this 577m awarded to conduct these trials. The US are putting themselves ahead of the rest of world in getting this comprehensive data and package of treatments lined up for future viral issues.
Were in I would say, or certainly at a stage likely to be included when this trial designs are established.
That has cheered me up (a bit!). Lol :)
No idea… one for the medical professionals.. Stanford uni did release a paper in 2020 which related to Interferon so maybe a chance there.
Won't those centres already be working on drugs / treatments, and prioritise those?
Thanks for clarifying, very helpful. Fingers crossed then
Size… I think the list are the centres that have been awarded the funding and not the drug… extract from release below. Happy to be corrected but thats how it reads to me
…..The AViDD centers will conduct research on the early-stage identification and validation of novel viral targets, with an eye to identify small molecules and biotherapeutics that directly block viral targets. “As drug candidates are identified and evaluated for properties such as potency and breadth, the most promising will enter late-stage preclinical development.” Importantly, the centers can draw on the resources of their industry partners to accelerate research, making use of the companies’ chemical libraries and expertise in moving candidates into the product development pipeline……
Does the list perhaps refer to the 'Centres' to be used as opposed to specific drugs/treatments ?
Disapointing not to be on the list / awarded funding
When he talks about teams that are conducting trials on other viruses of concern, it's not hard to believe he's referring to this: https://www.nih.gov/news-events/news-releases/nih-announces-antiviral-drug-development-awards
Despite the upcoming 25/5 update, A2P2 results will surely be our real signpost. My only thoughts then are, what a re-started A2P3 (fingers-crossed emoji) looks like - perhaps a more focussed target audience and therefore a hope of similar P3 DD-type high %'s. So, looking forward my related questions are these:
1. Is there really a need for a further PT, if we secure A2P3?, - I would hope no, and
2. If, in their excitement, SNG accept another PT invite, do we risk additional delay or further 'muddying of the waters' where both results even in part contradict each other (e.g. P2 & P3) .. in simple terms, can too many PT's be counter-productive? - I'm thinking yes, possibly.
Doc
Activ2 have helped EUAs off the back of phase 2 Covid-19.
I’m guessing they want that data to be Copper
Plated and correct because it may well show SNG improvement of progression to severe illness by more than 40%.
That would be very commercially sensitive
I agree RM can’t talk about takeovers or EUAs, but I really do hope that is going on behind the scenes.
Good analogy from Tommy that a platform trial is our lifeboat and would mean we rumble on. But we’ll be looking at a year+… trials just aren’t quick things.
Where the bloody hell is ACTIV-2 P2 data?! Can anyone think of any reason(s) why we shouldn’t have received it by now?
Kevinl1977
"Unlike many on here, I don’t get excited because RM had a little smile or because he looked like he knows it works - I think we’ve been there before and look what happened.
Just because we go on another trial, what will be different this time?
SOC hasn’t changed; we will however be targeting a specific group of hospitalised patients that have already shown statistical benefit from SNG001.
Time will tell, but until then I remain very cautious.
GLA"
YES. Wise words. Soon it will be the SNG rocket, golden tickets, etc. Cool detachment is needed after everything.
And still it's ludicrous to call that "stress testing" lol
In that dataset, there were 11 events (progression/death) in placebo and 3 in treatment.
I see the SP is recovering from this morning's woes
182 patients
“A handful”
You really are desperat.
You were more believable on Patents.
Give it up Sniff and move on to blockchain
Tommy
Thanks for sharing yet some more excellent posts.
Unlike many on here, I don’t get excited because RM had a little smile or because he looked like he knows it works - I think we’ve been there before and look what happened.
Just because we go on another trial, what will be different this time?
SOC hasn’t changed; we will however be targeting a specific group of hospitalised patients that have already shown statistical benefit from SNG001.
Time will tell, but until then I remain very cautious.
GLA
Lmao he called picking a handful of patients with certain characteristics (a post hoc subgroup analysis), "stress testing the data". A spin doctor of the poor.
Platform trial is potentially a year. But a platform trial is our lifeboat in choppy seas. If Activ2 is very positive and we’re on a PT with shown statistically significant results and let’s remember outstanding efficacy in the right patients. I don’t think we’d be waiting a year before someone bought us. Particularly if we were not only trialing Covid-19 but other viral infections
Agree Mr Costs.... looks pretty excited to me.... almost hyperventilating from excitement and relief!
Fair play from RM, he did sound positive.
Andrewcapp could be upgrading his trailer tent this time next year...
AJ316 ok :)
Sounded optimistic to me Having identified this respondent group to our drug which may included all viruses and regardless of age ? Seem like it could be a perfect for treatment for a clinician to save lives in hospitalised patients RM probably could not mention any commercial sensitive stuff ?